Welcome to our dedicated page for ALTERITY THERAPEUTICS SEC filings (Ticker: ATHE), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Alterity Therapeutics Limited filings document a foreign private issuer and development-stage biotechnology company reporting through Form 6-K and incorporated reports tied to Form S-8 and Form F-3 registration statements. The filings record ATH434 and MSA development updates, bioMUSE biomarker publications, FDA meeting communications, medical conference presentations, and Appendix 4C quarterly cash flow and activity reports.
Other disclosures cover shareholder meeting and proxy materials, substantial holding notices, share consolidation or split notices, board and governance changes, and capital-structure matters for securities traded as ASX: ATH and NASDAQ: ATHE.
Alterity Therapeutics Limited reports that Chief Executive Officer David Stamler, M.D., will present at the 46th Annual Canaccord Genuity Growth Conference on August 11, 2026 at 1:30 p.m. ET, with a live and archived webcast available through the company’s investor website.
The biotechnology company focuses on disease modifying therapies for Multiple System Atrophy (MSA) and related Parkinsonian disorders and is preparing to initiate a Phase 3 pivotal trial in MSA. Lead asset ATH434 has demonstrated clinically meaningful efficacy in a randomized, double-blind, placebo-controlled Phase 2 trial in MSA and has also generated positive data in an open-label Phase 2 trial in participants with advanced MSA.
Alterity Therapeutics Limited reported a pivotal quarter, securing FDA alignment at an End-of-Phase 2 meeting on the registrational pathway for ATH434 in Multiple System Atrophy. The agency indicated that a single pivotal Phase 3 trial plus confirmatory evidence, anticipated from the ATH434-201 Phase 2 study, could support a New Drug Application.
The planned Phase 3 trial will enroll about 200 patients, randomized 1:1 to ATH434 50 mg or placebo twice daily for 12 months, using the 11-item UMSARS Part I scale as the primary endpoint and offering an open-label extension. Alterity has also manufactured the first registration batch of ATH434 and received positive FDA Type C feedback on chemistry, manufacturing and control elements.
Strategic partnering and funding discussions with pharmaceutical companies continue alongside other financing options. As of 30 June 2026, cash and cash equivalents were A$37.3 million, with quarterly operating cash outflows of A$7.72 million and an estimated 5.2 quarters of funding available. A 1-for-50 share consolidation was completed following shareholder approval.
Alterity Therapeutics Limited reports that 18,443,495 quoted options trading on ASX under code ATHO will expire at 5.00pm (AEST) on 31 August 2026. Official quotation of these options will cease at the close of trading on Tuesday, 25 August 2026, four business days before expiry. Each option is exercisable at $0.50 per option, and holders who wish to exercise must submit a Notice of Exercise and cleared payment via the Automic Investor Portal by the expiry deadline.
Alterity is a clinical stage biotechnology company focused on disease modifying therapies for Multiple System Atrophy and related Parkinsonian disorders. Its lead asset, ATH434, has shown clinically meaningful efficacy in a randomized, double-blind, placebo-controlled Phase 2 trial, and the company is preparing to initiate a Phase 3 pivotal trial in MSA.
Alterity Therapeutics, a clinical stage biotechnology company, announced that Chief Executive Officer David Stamler, M.D., will participate in the virtual BTIG Biotechnology Conference 2026 on 28-29 July 2026, where he will host 1-on-1 meetings with investors in the United States.
The company develops disease modifying therapies for neurodegenerative diseases, focusing on Multiple System Atrophy and related Parkinsonian disorders. Alterity is preparing a Phase 3 pivotal trial in MSA for its lead asset ATH434, which has shown clinically meaningful efficacy and positive data in Phase 2 clinical studies.
Alterity Therapeutics Limited reports receiving an R&D tax refund of A$3,982,992 for the 2025 financial year, including A$43,117 in interest, under the Australian Government’s R&D tax incentive program.
The incentive provides a refundable tax offset of up to 43.5% for eligible R&D activities. Alterity states that this cash refund will provide important funding to continue developing its clinical programs, including its lead candidate ATH434 for Multiple System Atrophy, where it has completed Phase 2 trials and is preparing a Phase 3 pivotal study.